NEW YORK – Boston-based NanoView Biosciences has signed an exclusive agreement with Isaza Scientific to distribute Nanoview's ExoView platform in Spain and Portugal.
The research-use-only ExoView platform is an antibody labeling and imaging-based extracellular vesicle detection tool that provides high-resolution sizing, counting, and phenotyping. NanoView said that the platform requires minimal sample input, no sample prep or purification, and can be used directly with complex biological samples.
"Expanding access to our ExoView platform will enable the entire exosome field to move forward with accurate characterization of extracellular vesicles in life science research," NanoView CEO Jerry Williamson said in a statement.
Carlos Arribas, general manager at Izassa Scientific, added that "scientists across Spain and Portugal will be excited to have access to NanoView's unique exosome characterization technology, enabling them to better understand the role of extracelluar vesicles in biology, which is an emerging growth market in life science research."
Financial details of the agreement were undisclosed.
In October, NanoView signed an exclusive agreement with Alfatest to distribute Exoview in Italy.